Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Drug Manufacturers - Specialty & Generic

Healthcare
$25.93 -0.71%

-$0.24 today

Market cap
$805.79M
Beta
0.75
P/E (TTM)
14.3
EPS (TTM)
$2.34
52W Low $29.19High $50.79

Volume 0.49M

Average 0.50M

COLL Interest Expense

Cost of servicing the company's debt during the period.

Collegium Pharmaceutical, Inc.NASDAQ: COLL

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense dips below year-ago levels

Q1 FY2026 interest expense of $15.86M fell 23.7% year over year, behind the +110.4% change in trailing-twelve-month interest expense. Sequentially, it fell 84.9% from the prior quarter. Over 3 fiscal years it compounded at +9.2% a year.

Context

  • Interest expense amounted to 10.5% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -23.7% toward the trailing-twelve-month pace of +110.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.86M-84.9% QoQ
Last fiscal yearDec 2025
$82.31M+11.3% YoY
LTMMar 2026
$162.89M+110.4% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.7%——
1 year+11.3%——
3-year CAGR+9.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
82.31M USD
Year-over-year change
+11.3%
4-year CAGR
+40.7%

Interest Expense vs competitors

How COLL compares with its peers on the latest reported figures

  • COLL's LTM Mar 2026 interest expense of $162.89M is the highest of the 3 companies compared; the peer median is $13.83M.
  • Its year-over-year change of +110.4% is the 2nd highest of 3, against a peer median of +108.9%.
  • Interest expense amounts to 20.5% of revenue for COLL, versus a peer median of 19.9%.
COLL Competitors Peer median
Interest Expense for COLL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$162.89M +110.4%+9.2%20.5%
PCRXPacira BioSciences, Inc.LTM Mar 2026$14.9M -8.2%-25.7%2.0%
SCLXScilex Holding CompanyLTM Mar 2026$12.76M +226.0%+6.1%37.7%
LTGOLatigo Biotherapeutics Inc.—— ———
Peer median (excluding COLL) $13.83M+108.9%-9.8%19.9%

Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue276.87M463.93M566.77M631.45M780.57M
Cost of Revenue126.25M254.45M240.6M254.11M317.31M
Gross Profit150.62M209.49M326.17M377.34M463.26M
Gross Margin54.4%45.2%57.5%59.8%59.3%
Research & Development9.45M3.98M000
Selling, General & Admin118.96M172.19M159.21M182.98M276.17M
Operating Expenses132.99M176.17M159.21M207.45M276.17M
Depreciation & Amortization68.92M138.94M149.26M169.16M226.07M
EBITDA86.56M173.31M308.33M341.7M401.01M
EBITDA Margin31.3%37.4%54.4%54.1%51.4%
Operating Income17.63M33.32M166.96M169.9M187.08M
Operating Margin6.4%7.2%29.5%26.9%24.0%
Interest Income12K1.05M15.62M13.98M11.29M
Interest Expense21.01M63.21M83.34M73.97M82.31M
Other Income / Expenses(21M)(62.17M)(91.23M)(71.33M)(94.47M)
Income Before Tax(3.37M)(28.85M)75.73M98.57M92.62M
Pre-Tax Margin-1.2%-6.2%13.4%15.6%11.9%
Income Tax Expense(74.89M)(3.85M)27.58M29.38M29.75M
Net Income71.52M(25M)48.16M69.19M62.87M
Net Margin25.8%-5.4%8.5%11.0%8.1%
EPS (Basic)2.05(0.74)1.602.141.98
EPS (Diluted)1.86(0.74)1.291.861.73
Weighted Avg Shares34.94M33.83M33.74M32.27M31.71M
Weighted Avg Shares (Diluted)41.05M33.83M41.79M40.42M39.7M

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Intrinsic Alpha fair value

Locked

Current Price

$25.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.